Shuttle Pharmaceuticals Holdings annual stock-based compensation
2021
2022
2023
2024
2025
Shuttle Pharmaceuticals Holdings Stock-Based Compensation Growth & History (SHPH)
Shuttle Pharmaceuticals Holdings's stock-based compensation was $932,967 for fiscal 2025.
View full Shuttle Pharmaceuticals Holdings company overviewShuttle Pharmaceuticals Holdings annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $932,967 | $673,223 | +259.19% |
| 2024 | 2024-12-31 | $259,744 | $77,784 | +42.75% |
| 2023 | 2023-12-31 | $181,960 | −$55,587 | −23.40% |
| 2022 | 2022-12-31 | $237,547 | −$672,520 | −73.90% |
| 2021 | 2021-12-31 | $910,067 | — | — |
Shuttle Pharmaceuticals Holdings quarterly stock-based compensation
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $35,018 | −$502,028 | −93.48% |
| Q4 2025 | 2025-12-31 | $214,750 | $182,892 | +574.09% |
| Q3 2025 | 2025-09-30 | $134,318 | $89,043 | +196.67% |
| Q2 2025 | 2025-06-30 | $46,853 | −$24,309 | −34.16% |
| Q1 2025 | 2025-03-31 | $537,046 | $425,597 | +381.88% |
| Q4 2024 | 2024-12-31 | $31,858 | −$54,664 | −63.18% |
| Q3 2024 | 2024-09-30 | $45,275 | $7,692 | +20.47% |
| Q2 2024 | 2024-06-30 | $71,162 | $21,640 | +43.70% |
| Q1 2024 | 2024-03-31 | $111,449 | $103,116 | +1237.44% |
| Q4 2023 | 2023-12-31 | $86,522 | — | — |
| Q3 2023 | 2023-09-30 | $37,583 | $13,916 | +58.80% |
| Q2 2023 | 2023-06-30 | $49,522 | −$117,011 | −70.26% |
| Q1 2023 | 2023-03-31 | $8,333 | −$158,200 | −95.00% |
| Q3 2022 | 2022-09-30 | $23,667 | — | — |
| Q2 2022 | 2022-06-30 | $166,533 | — | — |
| Q1 2022 | 2022-03-31 | $166,533 | — | — |
Shuttle Pharmaceuticals Holdings stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, Shuttle Pharmaceuticals Holdings's stock-based compensation increased from $910,067 to $932,967, a change of $22,900. The latest reported quarter, Q1 2026, shows $35,018.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Shuttle Pharmaceuticals Holdings source filings ↗